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Rationale: Ongoing efforts to improve pulmonary gene transfer
thereby enabling gene therapy for the treatment of lung diseases,
such as cystic fibrosis (CF), has led to the assessment of a lentiviral
vector (simian immunodeficiency virus [SIV]) pseudotyped with the
Sendai virus envelope proteins F and HN.
Objectives: To place this vector onto a translational pathway to the
clinic by addressing some key milestones that have to be achieved.
Methods: F/HN-SIV transduction efficiency, duration of expression,
and toxicity were assessed in mice. In addition, F/HN-SIV was
assessed in differentiated human air–liquid interface cultures, pri-
mary human nasal epithelial cells, and human and sheep lung slices.
Measurements and Main Results: A single dose produces lung expres-
sion for the lifetime of the mouse (z2 yr). Only brief contact time is
needed to achieve transduction. Repeated daily administration leads
to a dose-related increase in gene expression. Repeated monthly ad-
ministration to mouse lower airways is feasible without loss of gene
expression. There is no evidence of chronic toxicity during a 2-year
study period. F/HN-SIV leads to persistent gene expression in human
differentiated airway cultures and human lung slices and transduces
freshly obtained primary human airway epithelial cells.
Conclusions: The data support F/HN-pseudotyped SIV as a promising
vector for pulmonary gene therapy for several diseases including
CF. We are now undertaking the necessary refinements to progress
this vector into clinical trials.
Keywords: lentivirus; cystic fibrosis; gene therapy; lung; gene transfer
Gene transfer to the airway epitheliumhas beenmore difficult than
originally anticipated, largely because of significant extracellular
and intracellular barriers in the lung (1). In general, viral vectors
are more adapted to overcoming these barriers than nonviral gene
transfer agents. Viral vectors that have a natural tropism for the
airway epithelium, such as those derived from adenovirus, adeno-
associated virus, and Sendai virus (SeV), have been evaluated for
cystic fibrosis (CF) gene therapy. SeV vector, in particular, leads
to log orders higher gene expression than nonviral formulation
when applied to the apical surface of airway epithelial cells (2, 3).
However, gene expression is transient and repeated administration
is inefficient (4, 5). These vectors are, therefore, unlikely to solve
the challenge of life-long gene therapy treatment for CF.
Lentiviral vectors are commonly pseudotyped with the G-
glycoprotein from the vesicular stomatitis virus (VSV-G) allowing
for a broad tissue tropism. However, VSV-G–pseudotyped vectors
are comparatively inefficient at transducing airway epithelial cells
and require the addition of tight junction openers, such as lyso-
phosphatidylcholine, to allow virus entry into airway cells (6, 7).
Several groups have attempted to further improve lentiviral vector
uptake into airway epithelium by changing the viral envelope pro-
teins. Glycoproteins from Ebola or Marburg virus that naturally
transfect airway epithelial cells by the apical membrane showed
early promise (8), but have more recently been superseded by viral
vectors pseudotyped with the influenza M2 envelope glycoprotein
(9), baculovirus protein GP64 (10), or the SeV-derived F and HN
envelope proteins (11, 12).
The F/HN-pseudotyped simian immunodeficiency viral vec-
tor (F/HN-SIV) transduces rodent airway epithelial cells in vitro
(12). Recently, we have shown that F/HN-SIV leads to persis-
tent expression in the mouse nose (.1 yr) importantly allowing
for monthly repeat administration without significant loss of
efficacy (11). It is currently unclear whether the prolonged ex-
pression is caused by vector integration into pulmonary stem or
progenitor cells, or by the long life-span of airway epithelial cells,
which as recently reported may have a half-life of up to 17
months (13). It is also unclear how on repeated administration
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AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
Gene transfer to the airway epithelium is more difficult than
originally anticipated. Until now viral gene transfer agents
have not been useful for the treatment of chronic lung
disease, such cystic fibrosis (CF), because of immunoge-
nicity, which prevents successful repeat administration.
Lentivirus-based vectors are a notable exception.
What This Study Adds to the Field
Moving novel therapies to the clinic requires that relevant
evidence for safety and efficacy is gathered in appropriate
models. Here, we provide a body of supportive evidence for
F/HN-pseudotyped simian immunodeficiency virus as a po-
tential gene transfer agent for CF including lifetime gene
expression and efficient repeat administration in mouse lung,
lack of chronic toxicity, and persistent gene expression in
human ex vivo models.
the viral vector evades the immune system, although interestingly
liposomes that contain SeV proteins (HVJ-liposome) can also be
repeatedly administered (14). This feature, and the efficient
and prolonged expression profile and the ability to administer
through the apical surface of the respiratory epithelium with-
out preconditioning, makes the vector an attractive candidate
for treating CF, which is a chronic disease and requires life-
long correction of the genetic defect in airway epithelial cells.
Here,wehave further developed theF andHN–pseudotyped SIV
toward clinical evaluation. We show that repeated administration to
the mouse lower airways is feasible. We also confirm the long-term
safety profile of this viral vector and show that it transduces the
relevant human airway epithelial cells required for CF gene therapy.
METHODS
Viral Vector Production
Purified and concentrated F/HN-SIV expressing firefly luciferase (F/HN-
SIV-Lux) or enhanced green fluorescent protein (F/HN-SIV-GFP) under
the transcriptional control of the cytomegalovirus (CMV) enhancer/
promoter were prepared and titrated as previously described (11) (see
online supplement for further details).
Mouse Lung Transfection
Female C57BL/6N mice (6–8 wk old) were used (see online supplement).
A 100-ml viral vector in Dulbecco’s phosphate-buffered saline (D-PBS)
was administered to the mouse nose and “sniffed” into the lung as pre-
viously described (15) (see RESULTS and FIGURES for details about vector
titers used) and gene expression quantified (see online supplement).
For the daily repeat administration experiments, groups of mice were
treated over 10 dayswith either nine daily doses ofD-PBS followedby a sin-
gle dose of F/HN-SIV-Lux, five daily doses of D-PBS followed by five daily
doses of F/HN-SIV-Lux, or 10 daily doses of F/HN-SIV-Lux. Gene expres-
sion was analyzed 28 days after the final F/HN-SIV-Lux administration.
For themonthly repeat administration experiments groups ofmicewere
transduced with either one dose of F/HN-SIV-Lux (single-dose group), or
two doses of F/HN-SIV-GFP (Day 0, Day 28), followed by F/HN-SIV-Lux
onDay 56 (repeat-dose group). Importantly,mice receivingF/HN-SIV-Lux
(single-dose group) and F/HN-SIV-Lux on Day 56 (repeat-dose group)
were of similar age and were transduced at the same time. Gene expression
was analyzed 28 days after F/HN-SIV-Lux administration.
Toxicology
Over the 24-month study period mice were carefully observed daily and
were given a full clinical examination every 2 weeks (including palpation
of the abdomen for tumors) by an experienced animal technician, and
bodyweight was recorded. Histologic assessment was performed in mice
that showed signs of illness throughout the study period. In addition,
lungs from asymptomatic mice culled at the end of the 24-month study
period were also analyzed (see online supplement).
Histologic Assessment of GFP Expression
Mouse lungs were transduced with F/HN-SIV-GFP (108 TU/mouse in
100 ml) by nasal sniffing. Animals receiving D-PBS only were used as
negative controls (n¼ 4 per group). One month after transduction animals
were culled and GFP expression was assessed in lung tissue (see online
supplement).
Gene Transfer into Relevant Preclinical Model
Gene transfer into human air–liquid interface (ALI) cultures, human
nasal brushings, and lung slices was performed as described in the
online supplement.
Statistical Analysis
Analysis of variance followed by a Bonferroni post hoc test or Kruskal-
Wallis test followed by Dunn multiple comparison post hoc test was
performed for multiple group comparison after assessing parametric
and nonparametric data distribution with the Kolmogorov-Smirnov nor-
mality test, respectively. An independent Student t test or aMann-Whitney
test was performed for two-group parametric and nonparametric data as
appropriate. Pearson correlation was performed for parametric data. All
analyses were performed using GraphPad Prism4 (GraphPad Software,
Inc., La Jolla, CA) and the null hypothesis was rejected at P less than 0.05.
RESULTS
Gene Expression in Mouse Lung Persists and Is Stable
We first assessed if F/HN-SIV produced measurable levels of lu-
ciferase inmurine lower airways (lungs), and if this expression was
dose-related. Mice were transduced with F/HN-SIV-Lux (107 or
108 TU/mouse in 100 ml total volume) by nasal sniffing (n ¼ 8 per
group) or received D-PBS (n ¼ 8). Two days after transduction
mice were culled and luciferase expression quantified in lung
homogenates. Luciferase expression was detectable and dose-
related (107 TU/mouse, 2 6 0.3 relative light units [RLU])/mg
protein; 108 TU/mouse, 27 6 6.4 RLU/mg protein, P , 0.01;
D-PBS, 0.01 6 0.03 RLU/mg). However, gene expression was
also production batch-related (see online supplement).
We next assessed if expression in mouse lungs persisted. Mice
were transduced with F/HN-SIV-Lux (5 3 108 TU/mouse in
100 ml total volume) by nasal sniffing (n ¼ 8 in two independent
experiments) or received D-PBS (negative controls, n ¼ 6) and
luciferase expression was quantified using in vivo biolumines-
cence imaging (BLI) at regular intervals for up to 22 months.
Luciferase-mediated photon emission was detectable in all trea-
ted mice 2 months after transduction (SIV, 362,660 6 63,922
photons/s/cm2, n ¼ 8; D-PBS, 66,5356 4,868 photons/s/cm2, n ¼
6; P , 0.005). Seven out of eight mice survived for 16 months
and four out of the eight mice survived until termination of the
experiment at 22 months. All of the SIV transduced mice had
detectable luciferase expression at all time points. Photon emis-
sion increased modestly, but significantly (P , 0.005), over time
(SIV at 2 mo, 381,123 6 70,665 photons/s/cm2; at 16 months,
543,1566 65,234 photons/s/cm2; n¼ 7 mice with data for both time-
points). This was maintained at 22 months (2 mo, 367,4856 115,923
photons/s/cm2; 22 months, 1,407,0006 435,790 photons/s/cm2; n ¼ 4
mice with data for both time-points). In contrast, photon emis-
sion in D-PBS–treated mice remained stable over the same time
period (Figures 1A and 1B).
An increase in photon emission may indicate an increase in
luciferase expression potentially caused by an increase in the
number of luciferase-expressing cells over time or may be a pe-
culiarity of BLI. We therefore repeated the experiment compar-
ing BLI with post-mortem quantification of luciferase expression
in lung tissue homogenates in the same animals. Mice were trans-
duced with F/HN-SIV (107 TU/mouse, n ¼ 8–12 per time-point)
and at regular intervals over a 24-month period (for technical
reasons BLI could only be performed between 6 and 24 months
after gene transfer) and post-mortem quantification of lucifer-
ase expression in lung tissue homogenate was performed in
cohorts of mice. Similar to results described previously photon
emission significantly (P , 0.001) increased over the study pe-
riod (BLI at 6 mo, 87,915 6 8,871 photons/s/cm2; BLI at 24 mo,
310,334 6 36,274 photons/s/cm2) (Figure 1C), whereas detect-
able levels of luciferase in tissue homogenate remained stable
(Figure 1D). There was no correlation between in vivo photon
emission and luciferase expression quantified in tissue homoge-
nates (Spearman r ¼ 0.205; P ¼ 0.11; n ¼ 63 paired data points
from 6–24 mo). However, luciferase expression quantified in
tissue homogenates correlated well with photon emission from
the same animal when lungs were extracted before BLI (Figure
1E) (Spearman r ¼ 0.75; P ¼ 0.01; n ¼ 11 paired data points at
24 mo), which implies that photon quenching may occur in vivo.
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Additional technical considerations relating to limitations of
BLI and virus batch-to-batch variability became apparent in this
study (see online supplement).
To determine what cell types were transduced in the lung we
transfected mice with F/HN-SIV-GFP (108 TU/mouse) or D-PBS
(n ¼ 4 per group) by nasal sniffing and assessed GFP expression
1 month after transduction. GFP expression was detectable in
airway epithelial cells, and also in the alveolar region (Figure 1F).
F/HN-SIV Requires Only Short Contact Time to Achieve
Efficient Transduction
We compared prolonged contact time of the vector with the na-
sal epithelium (by perfusion) with very brief contact time (sniff-
ing). The latter led to equally efficient transduction of the nasal
epithelium as the former (Figures 2A and 2B). This suggests that
a short contact time between the viral vector and the target cell
may be sufficient for efficient vector uptake into the cells, of
potential importance in future clinical trials.
Gene expression in the nose also persisted for 15–22 months
in seven out of eight mice, but in contrast to the lung gradually
declined by approximately 60% over this period (SIV Month 2,
1,309,000 6 316,612 photons/s/cm2; SIV Month 15, 583,951 6
228,804 photons/s/cm2, P , 0.05, n ¼ 7 per group; D-PBS
Month 15, 53,021 6 2,325 photons/s/cm2, P , 0.005), which
may be caused by different cell types being transduced in nose
and lung or different turnover rates of the cells at these two
sites. Consistent with our previous data using nonviral gene trans-
fer agents (16), intranasal administration of luciferin (the substrate
for luciferase) boosted F/HN-SIV-Lux–derived photon emission
in mice that were negative after intraperitoneal administration
of luciferin (Figure 2C).
Daily Repeat Administration to the Lung Is Feasible
Although gene expression after a single dose of F/HN-SIV persists
for the lifetime of the animal, a single dosemay not be sufficient to
achieve therapeutic benefit in humans. It is, for example, conceiv-
able that the total volume required for delivery of the optimal vec-
tor titer to the human lung may be too large for a single dose and
administration may have to be split into several doses to accom-
modate the volume. We, therefore, assessed if repeated daily
Figure 1. F/HN simian immu-
nodeficiency virus (SIV) trans-
duction leads to persistent gene
expression in mouse lung. Mice
were transduced with F/HN-SIV-
luciferase (Lux) (5 3 108 TU/
mouse) by nasal sniffing (n ¼ 8
in two independent experiments)
or received phosphate-buffered
saline (PBS) (negative controls,
n ¼ 6). Lux expression was
quantified using biolumines-
cence imaging (BLI) or in tis-
sue homogenate at regular
intervals for up to 24 months.
(A) BLI 2–22 months after
transduction. Representative
images of two mice reaching
the 22 months time point are
shown. (B) Quantification of in
vivo BLI over time (black lines,
n ¼ 8) or PBS (red lines, n ¼ 6).
Each line represents photon
emission over time in one
animal. Solid and dotted lines
represent independent experi-
ments. ***P , 0.005 when
compared with Month 2. BLI
(C) and Lux expression in lung
tissue homogenate (D) was
repeated at regular intervals
over 24 months in a third in-
dependent experiment (107
TU/mouse, ¼ 8–12 per time-
point). For technical reasons
BLI could only be performed
between 6 and 24 months
after gene transfer. ***P ,
0.005 when compared with
Month 6. Quantification of
Lux expression in lung tissue homogenate was performed at regular intervals over the 24-month study period. Each dot represents one animal.
Horizontal bars represent the group median. (E) Correlation between Lux expression quantified in tissue homogenates and photons emitted from
extracted lungs (representative images from 11 extracted lungs are shown). Each dot represents one animal. (F) Detection of green fluorescent protein
(GFP) expression in lung after transduction with F/HN-SIV-GFP (108 TU/mouse). Transduced GFP-positive cells were identified using fluorescent
microscopy (original magnification, 320). (i) PBS-treated negative control. (ii and iii) Tissue sections from F/HN-SIV-GFP–treated mice showing
GFP-positive cells in airways (arrows) and alveoli. Representative images from four mice per group are shown. RLU ¼ relative light units.
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administration of the viral vector is feasible and if this leads to
incrementally increased gene expression compared with a single
dose. Mice (n ¼ 8 per group) were treated with either F/HN-
SIV-Lux daily for 10 days (106 TU/day in 100 ml) or with PBS
(100 ml) for 5 days followed by 5 days of F/HN-SIV-Lux (106
TU/day) or with D-PBS for 9 days followed by 1 day of F/HN-
SIV-Lux (106 TU/day); Lux expression was quantified 28 days
after the last dose. Gene expression was significantly correlated
(Pearson r2 ¼ 0.61; P . 0.0001) with the number of F/HN-SIV-
Lux doses given (Figure 3A) and indicated that daily repeat
Figure 1. (Continued).
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administration is feasible and significantly increases transduction
efficiency.
Monthly Repeat Administration to the Lung Is Feasible
Although a single dose of F/HN-SIV generates persistent gene
expression for approximately 2 years in mice (lifetime of the
animal) a single dose is unlikely sufficient to achieve clinical ben-
efit for the lifetime of a patient with CF. Therefore, a crucial ques-
tion is whether the vector can produce gene expression on repeated
administration to the lung. As shown previously, daily administra-
tion was feasible, but this timeframe is unlikely to be sufficient for
the development of effective immune responses to the viral vector.
Figure 2. F/HN simian immunodefi-
ciency virus (SIV) requires only short
contact time to achieve efficient trans-
duction. Luciferase (Lux) expression
was compared in mice receiving F/
HN-SIV-Lux (3–4 3 108 TU/mouse in
100 ml) by slow perfusion (1.3 ml/min,
n ¼ 10) or as bolus administration by
nasal sniffing (n ¼ 8). (A) Biolumines-
cence in vivo signal in the mouse nose.
Representative images of three mice
are shown. (B) Quantification of in vivo
bioluminescence in mouse nose after
slow perfusion or nasal sniffing of the
vector. Each dot represents one animal.
Horizontal bars represent the group me-
dian. (C) Bioluminescence in vivo signal
in mouse nose after intraperitoneal (IP)
or intranasal (IN) administration of lucif-
erin. Representative images of two of
five mice are shown. Lux expression af-
ter slow perfusion of the F/HN-SIV-Lux
has been published previously (11).
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We therefore conducted repeat administration experiments at
monthly dosing intervals, a period we have shown to be sufficient
for the development of an immune response to other viral vectors
(5, 17). Mice were either treated with one dose of F/HN-SIV-Lux
(single-dose group) or two doses of F/HN-SIV-GFP (Day 0, Day
28), followed by F/HN-SIV-Lux on Day 56 (repeat-dose group).
All mice received 107 TU in 100 ml per dose (n ¼ 20 per group)
and gene expression was analyzed 28 days after F/HN-SIV-Lux
administration. All mice received only one dose of vector carrying
a luciferase reporter gene to avoid interference of antiluciferase
antibodies. As shown in Figure 3B luciferase expression levels after
one and three doses of the viral vector were identical and at this
vector titer 4 log orders above background levels (P , 0.01).
No Evidence of Chronic Toxicity Was Seen during a Two-Year
Follow-up Period
Chronic toxicity caused by insertional mutagenesis is a potential
concern with this vector. Here, we compared 24-months survival
of mice treated with F/HN-SIV-Lux (107 TU/mouse, n ¼ 99 at
start of the experiment) or D-PBS (n ¼ 48 at start of the ex-
periment). Mortality (Figure 4A) and weight (Table 1) in both
groups was similar. We also assessed the lungs of D-PBS– or F/
HN-SIV-Lux– (107 TU/mouse, n ¼ 12 per group) treated mice
histologically 24 months after nasal sniffing; there were no dif-
ferences in any of the key histologic markers (Figures 4B–4D).
Eleven D-PBS and seven F/HN-SIV–treated mice were culled
because they showed signs of illness or were found dead during
the study. Histologic examination revealed a range of pathology
commonly found in aging C57BL/6N mice equally distributed
between the two groups (Table 2).
F/HN-SIV Transduction of Human Ex Vivo Models
Is Feasible
F/HN-SIV achieves persistent gene expression in differentiated
human ALI cultures. To assess the efficiency of the viral vector
in relevant human tissues we transduced human ALIs with F/
HN-SIV-Lux at multiplicity of infection (MOI) 25 or 250 (n ¼ 5
per group), with D-PBS control (n ¼ 3), or with GL67A, the most
efficient nonviral gene transfer agent for airway epithelium. The
latter was complexed with a eukaryotic expression plasmid express-
ing luciferase (10 mg pCIKLux per ALI equivalent to 3 3 1012
plasmids and an approximate MOI of 7 3 106) (n ¼ 3) and
luciferase expression followed using BLI for 3 months (repre-
sentative images are shown in Figure 5A). F/HN-SIV–mediated
expression was dose-related and persisted for at least 3 months
without the loss of activity. In contrast, transfection with GL67A/
pCIKLux was only barely detectable at an early time-point (Day 2)
after transfection (Figure 5B). Lipid-mediated gene transfer was
associated with cell damage as indicated by the appearance of
small holes in the ALIs; this was not seen with exposure of the
ALIs to the lentiviral vector (data not shown).
F/HN-SIV transduces primary human pulmonary cells. We
assessed if F/HN-SIV transduces primary human airway epithe-
lial cells obtained from nasal brushings or human lung slices gen-
erated from lung resection tissue (Figure 6A). Nasal brushings
were transduced with F/HN-SIV-Lux at an MOI of 25 and 250
or treated with D-PBS (n ¼ 6 per group) and luciferase expres-
sion was quantified 24 hours after transduction (cell viability
precludes longer time scales). Luciferase expression was sig-
nificantly (P , 0.005) increased compared with PBS control
subjects (Figure 6B). These results were confirmed in an inde-
pendent experiment (MOI 25, 9.7 3 106 6 0.9 3 106; MOI 250,
1.5 3 107 6 1.6 3 106; negative control subjects, 2,762 6 241
RLU/mg protein, n ¼ 4 per group)
F/HN-SIV achieves persistent gene expression in human and
sheep lung slices. Precision-cut human lung slices were transduced
with F/HN-SIV-Lux (2 3 107 TU/slice), or remained untrans-
duced, and luciferase expression quantified for 14 days after trans-
duction. Assessment of later time-points is currently not feasible
because of limited tissue viability (Figure 6C). Two independent
experiments were performed (see open and closed symbols in the
figure) but data were pooled to allow for robust statistical analysis.
Significant (P , 0.001) and stable gene expression was detectable
for at least 14 days (P , 0.05) after gene transfer.
We also repeated these experiments in sheep lung slices (two
independent experiments), which generally survive longer than
human lung sliceswhen cultured (unpublisheddata). Significant (P,
0.001 to P , 0.05) and stable luciferase expression was de-
tectable at all time-points for at least 26 days after transduction
Figure 3. Daily and monthly repeat administration to the lung is feasi-
ble. (A) Daily readministration. Mice (n ¼ 8 per group) were treated
with either F/HN simian immunodeficiency virus (SIV) luciferase (Lux)
for 10 days (106 TU/day) or with D phosphate buffered saline (PBS) for
5 days followed by 5 days of F/HN-SIV-Lux (106 TU/day) or with D-PBS
for 9 days followed by 1 day of F/HN-SIV-Lux (106 TU). Lux expression
was analyzed 28 days after F/HN-SIV-Lux administration. (B) Monthly
readministration. Mice were either treated with one dose of F/HN-SIV-
Lux (single-dose group) or two doses of F/HN-SIV-GFP (Day 0, Day 28),
followed by F/HN-SIV-Lux on Day 56 (repeat-dose group). All mice receive
107 TU/dose (n ¼ 20 per group) and gene expression was analyzed 28
days after F/HN-SIV-Lux administration. Each dot represents one animal.
Horizontal bars represent the group median. Dotted line represents nega-
tive control values, ***P , 0.0001 when compared with 5 and 10 doses,
**P , 0.01 when compared with 10 doses. RLU ¼ relative light units.
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(Figure 6D). These results indicate that F/HN–SIV is able to
transduce primary human and sheep pulmonary cells and pro-
vides persistent expression.
DISCUSSION
The efforts of one of our team to improve pulmonary gene trans-
fer and enable gene therapy for the treatment of lung diseases,
such as CF, have led to the development of a lentiviral vector
pseudotyped with the SeV envelope proteins F and HN (12).
Moving novel therapies to the clinic requires that relevant ev-
idence for safety and efficacy is gathered in appropriate models.
Here, we begin to place this vector onto a translational pathway
to the clinic and provide a body of supportive evidence for F/
HN-pseudotyped SIV as a potential gene transfer agent for CF.
We show that (1) a single dose produces lung expression for the
life-time of the mouse (z2 yr); (2) only brief contact time (sec-
onds) is needed to achieve transduction; (3) repeated daily ad-
ministration leads to a dose-related increase in gene expression;
(4) repeated monthly administration to mouse lower airways is
feasible without loss of gene expression; (5) there is no evidence
of chronic toxicity during a 2-year study period; and (6) F/HN-
SIV transduction generates persistent gene expression in human
differentiated airway cultures and freshly obtained human lung
slices and transduces freshly obtained primary human airway
epithelial cells.
At least two previous studies have shown that lentiviral vector–
mediated transduction of mouse lung leads to persistent (15
and 24 mo) gene expression in the murine lower airways (18,
19). However, both studies used a VSV-G–pseudotyped lenti-
viral vector, which almost exclusively transduces alveolar mac-
rophages, rather than lung epithelial cells. In addition to the
airway epithelium, the target for CF gene therapy, cells in the
peripheral lung (a mixture of pneumocytes and macrophages)
are transduced after bolus administration of the viral vector
by nasal sniffing, which may lead to pooling of liquid in the
Figure 4. No evidence of chronic toxicity
during 2-year follow-up period. (A) Twenty-
four months survival of mice treated with F/
HN simian immunodeficiency virus (SIV) lu-
ciferase (Lux) (107 TU/mouse, n ¼ 99 at start
of the experiment) or phosphate-buffered sa-
line (PBS) (n ¼ 48 at start of the experiment)
by nasal sniffing. Comparison of lympho-
cytes (B), edema (C), and inflammation (D)
in mouse lung 24 months after F/HN-SIV-Lux
or PBS treatment. Each dot represents one
animal. Horizontal bars represent the group
median.
TABLE 1. MOUSE WEIGHTS 6, 15, AND 24 MONTHS AFTER LUNG
TRANSDUCTION WITH F/HN-SIV-LUX OR PBS ADMINISTRATION
Months After Treatment PBS-treated Mice 8 g SIV-treated Mice 8 g
6 24.9 (0.5) n ¼ 48 25.4 (0.3) n ¼ 71
15 30.7 (0.7) n ¼ 47 31.4 (0.8) n ¼ 35
24 30.1 (1.4) n ¼ 36 29.1 (1.1) n ¼ 12
Definition of abbreviations: LUX ¼ luciferase; PBS ¼ phosphate-buffered saline;
SIV ¼ simian immunodeficiency virus.
Mean weights (6 SEM) are shown. There were no differences between PBS-
and SIV-treated mice.
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peripheral lung. To determine transduction efficiency of airway
epithelium more accurately the viral vector needs to be admin-
istered by nebulization. Further work is now warranted to de-
termine whether F/HN-SIV is stable in clinically approved
nebulizers and that virus production can be scaled up to the extent
required for clinical studies. We are currently assessing if F/HN-
SIV is stable in clinically approved nebulizers and preliminary
results indicate that infectivity after nebulization is retained (data
not shown); and scaling up vector production to allow us to move
into in vivo nebulization experiments in the near future.
Although expression levels in the lung are completely stable
over the 2-year study period, those in the nasal epithelium de-
clined by approximately 60%. The latter is consistent with our
previous data (11) and may relate to different cell types being
transduced in the lung (airway epithelium and alveolar cells)
and nose (mainly ciliated airway epithelial cells) (11) and dif-
ferent turnover rates of these cells at these two sites. Although,
we do not have information about turnover of nasal airway
epithelium, Rawlins and Hogan (13) have shown that the half-
life of ciliated airway epithelial cells in the mouse trachea and
lung differs (trachea, average half-life 6 mo; lung, average half-
life 17 mo).
We have previously shown that prolongation of contact time
between nonviral gene transfer agents and the airway epithelium
significantly increases gene expression (20). In our previous
study, we therefore slowly perfused F/HN-SIV (1.3 ml/min) onto
the mouse nasal epithelium to maximize transduction (11).
Transduction efficiency in the nasal epithelium after adminis-
tration of a bolus of fluid that is rapidly (seconds) sniffed into
the lung led to similar levels of photon emission. This implies
that brief contact time between F/HN-SIV and the target cell
may be sufficient for efficient vector uptake into the cells, which
is an important factor for clinical translation. F/HN-SIV there-
fore mimics SeV (2) from which the F and HN envelope pro-
teins were derived.
We and others have previously shown that repeated admin-
istration of lentiviral vectors to themouse nasal epithelium is fea-
sible (10, 11). To move our translational research a step closer
to clinical relevance we now assessed repeat administration of
the vector in the lung. Two types of repeat administration ex-
periments were performed: daily and monthly. The former was
assessed because it is conceivable that the total volume required
for delivery of a specific vector titer to the human lung may be
too large for a single dose and administration may have to be
TABLE 2. CAUSE OF MORTALITY OF PBS- AND F/HN-SIV–TREATED
MICE OVER A 24-MONTH PERIOD
Treatment Death (mo after treatment) Diagnosis
PBS 15 Found dead
PBS 18 Lymphoma
PBS 19 Lymphoma
PBS 20 Lymphoma
PBS 20 Inconclusive
PBS 21 No pathology found
PBS 21 Lymphoma
PBS 23 No pathology found
PBS 23 Found dead
PBS 23 Lymphoma
PBS 24 Found dead
SIV 3 Peritonitis
SIV 13 Found dead
SIV 17 Found dead
SIV 19 Pancreatic tumor
SIV 21 Multiorgan inflammation
SIV 24 Found dead
SIV 24 Multifocal lymphocytic
inflammation
Definition of abbreviations: PBS ¼ phosphate-buffered saline; SIV ¼ simian im-
munodeficiency virus.
Figure 5. Persistent gene expression in differentiated air–
liquid interface (ALI) cultures. Differentiated human ALI
cultures were transduced with F/HN simian immunodefi-
ciency virus (SIV) luciferase (Lux) at multiplicity of infec-
tion (MOI) 25 or 250 (n ¼ 5 per group), transfected with
GL67A complexed to a eukaryotic expression plasmid
expressing Lux (10 mg pCIKLux per ALI equivalent to
3 3 1012 plasmids and an approximate MOI of 7 3 106)
(n ¼ 3) or treated with phosphate-buffered saline (PBS)
(negative control, n ¼ 3). Lux expression was followed
using bioluminescence imaging for 3 months. (A) Repre-
sentative images are shown. (B) Quantification of Lux ex-
pression over 3 months.
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split into several doses to accommodate the volume. Here, we
show that daily repeat administration is feasible and leads to
a dose-related increase in gene expression. Although important,
we have not yet addressed the question if “split-dose” delivery
of a specific vector titer (e.g., 10 doses of 107 TU) offers advan-
tages over “single-dose” delivery of the same vector titer (e.g.,
one dose of 108 TU), which may also be a relevant translational
research question. Although efficient daily-repeat administra-
tion is encouraging, this time-frame is generally not considered
to be sufficient to induce robust immune responses to the viral
vector. To confirm that long-term F/HN-SIV repeat administra-
tion to the lower airways is feasible viral vector was adminis-
tered monthly over a 3-month period. This dosing interval may
be of clinical relevance and is also an accepted timeframe for
the induction of robust immune responses. Uniquely for a viral
vector (in our hands), luciferase expression levels after one and
three doses were identical and more than 4 log orders higher
than in untransduced control mice.
Another important consideration for translational develop-
ment of a gene transfer agent is safety. The occurrence of leukemia
and myelodysplasia in some patients with primary immunodefi-
ciencies after treatment with g retroviral vector-transduced bone
marrow (21) raises concerns about the safety of integrating viral
vectors. The risk of insertional mutagenesis in slowly turning over
differentiated lung epithelium is unknown, but is likely to be
lower than in rapidly dividing bone marrow cells. In addition,
the improved design of self-inactivating lentiviral vectors has im-
proved safety (21). Here we compared survival, weight, and lung
histology during a 24-month study period and did not see any
differences between F/HN-SIV– and PBS-treated mice. We in-
cluded only female mice in the study because they can be more
readily housed together for prolonged periods of time. It is un-
likely that the toxicology profile in male mice would be signifi-
cantly different. However, before progression into clinical trial a
good laboratory practice (GLP)-toxicology study, including male
and female animals and dose-ranging, has to be performed. De-
spite the encouraging toxicology profile of our current vector
configuration we plan to assess further modifications before final
vector selection for clinical trials, including the use of mammalian
promoters and ubiquitous chromatin opening elements. The for-
mer have been shown to reduce the risk of insertional muta-
genesis compared with strong viral promoters (22), whereas the
latter may reduce gene silencing (22). The ability to administer
;
Figure 6. F/HN simian immunodeficiency virus (SIV) transduces pri-
mary human pulmonary cells. (A) Microscopic section showing primary
human airway epithelial cells obtained from nasal brushings (left, GC ¼
goblet cell, CC ¼ ciliated airway epithelial cell) or human lung slices
(right, AW ¼ airway, P ¼ parenchyma). (B) Nasal brushings were trans-
duced with F/HN-SIV-luciferase (Lux) at a multiplicity of infection (MOI)
of 25 and 250 or treated with phosphate-buffered saline (PBS) (nega-
tive control) and Lux expression was quantified 24 hours after trans-
duction. Each dot represents one sample. Horizontal bars represent the
group median. ***P , 0.005 when compared with negative controls.
(C) Human lung slices were transfected with F/HN-SIV-Lux (2 3 107
TU/slice) or remained untransfected (negative control) and Lux expres-
sion quantified 2, 7, and 14 days after transduction. Two independent
experiments were performed (open and closed symbols). (D) Sheep
lung slices were transfected with F/HN-SIV-Lux (2 3 107 TU/slice) or
remained untransfected (negative control) and Lux expression quanti-
fied up to 26 days after transduction. Two independent experiments
were performed (open and closed symbols). Each dot represents one
animal. Horizontal bars represent the group median. *P , 0.05, **P ,
0.01, ***P , 0.005 when compared with negative control. RLU ¼
relative light units.
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this vector repeatedly and efficiently also opens the possibility
of using nonintegrating lentiviral vectors (23), which may fur-
ther reduce the genotoxic risk.
As part of our translational pathwaywenext determinedwhether
F/HN-SIV is able to transduce human tissues. We have previously
shown that F/HN-SIV can transduce fully differentiated humanALI
cultures when analyzed 5 days after transduction (11). These cul-
tures mimic human airway epithelium and are difficult to transfect
(24). Here, we have extended these studies and show that F/HN-
SIV–mediated expression in ALIs is stable; persists for at least 3
months (the length of the experiment); and is higher than GL67A-
mediated expression, which in our hands is currently the most
efficient nonviral vector. Preliminary experiments indicated that
in contrast to lipid-mediated gene transfer, F/HN-SIV does not
seem to damage the ALI cultures, but more extensive studies are
required to determine acute toxicity in vitro and in vivo.
To further evaluate the viral vector in even more relevant tis-
sues we assessed freshly obtained human primary airway cells
and showed that F/HN-SIV-Lux transduction leads to significant
levels of luciferase expression. We performed only short-term
(24 h) experiments to avoid potential cell division, which would
have affected interpretation of the results. Collection of primary
cells by nasal brushings exposes the basolateral membrane of
these cells and we cannot exclude the possibility that the vector
may have entered the cells by this route. However, experiments
performed in mice in vivo and in ALI cultures clearly show that
F/HN-SIV can transduce airway epithelial cells when applied to
the apical membrane without the need to coadminister agents to
open tight junctions. There was no difference in gene expression
when cells were transduced with an MOI of 25 or 250. In future
experiments the MOI will be further reduced to determine the
minimum MOI for efficient transduction.
We also assessed F/HN-SIV in precision-cut human lung sli-
ces. Expression in both experiments was stable and persisted
for at least 14 days, after which the experiment was terminated
because of reduced tissue viability. Although we have not deter-
mined which cells express the recombinant protein these studies
show that persistent SIV-mediated transduction into human pul-
monary cells is feasible and is not prevented by viral restriction
factors.We also transduced ovine lung slices, which are generally
more resilient when cultured (Nikki Newman, personal commu-
nication); stable luciferase expression was detectable for at least
26 days. These data support the future use of these models in the
clinical development of this vector.
SeV shares high sequence homology with human parainfluenza
virus and preexisting immunity may be a factor. Interestingly, Slo-
bod and coworkers (25) assessed SeV-vaccination against human
parainfluenza virus and reported evidence of immunogenicity in
three of nine vaccinees despite preexisting, cross-reactive immu-
nity presumably induced by previous exposure to human para-
influenza virus-1. Although this initial study is encouraging, the
effects of preexisting humoral immunity on virus transduction
efficiency is something we will address as a high priority.
Gene transfer to the airway epithelium is more difficult than
originally anticipated. Until now viral gene transfer agents have
not been useful for the treatment of chronic lung disease, such
as CF, because of immunogenicity, which prevents successful
repeat administration. Lentivirus-based vectors are a notable ex-
ception. Moving novel therapies to the clinic requires that rele-
vant evidence for safety and efficacy is gathered in appropriate
models. Here, we begin to place this vector onto a translational
pathway to the clinic and provide a body of supportive evidence
for F/HN-pseudotyped SIV as a potential gene transfer agent for
CF including (1) lifetime gene expression and efficient repeat
administration in mouse lung, (2) lack of chronic toxicity, and
(3) persistent gene expression in human ex vivo models.
The data presented here support F/HN-SIV as a promising
vector for pulmonary gene therapy, with potential for many dis-
eases including CF. We are currently undertaking the next crit-
ical steps (vector optimization and virus production) in this
developmental process toward clinical evaluation and are im-
proving vector optimization and viral production methods to
support progression into early phase trials.
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